Treatment of age-related cognitive decline using genetically modified viral vectors
AssigneeBioviva USA Inc.
InventorsElizabeth Louise Parrish, Patrick Ellison Sewell, Jason R. Williams
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for treating or prophylactically treating age-related cognitive decline associated with dementia by administering recombinant viral vectors designed to deliver TERT and/or KL (Klotho) genes to the patient. The TERT and/or KL genes are packaged within one or more AAV viral vectors and administered to the CNS of the patient via intranasal and/or intrathecal injection. The therapy can provide improvements in cognitive function as evidenced by improved Folstein/MMSE scores over time.
Claims16
A method for treating age-related cognitive decline in a human, the method comprising:
- intranasally administering a therapeutically effective amount of a first recombinant viral vector, a second recombinant viral vector, and a third recombinant viral vector, each at a dose of at least 2×1013 GC, to a human subject in need thereof,
- wherein the first recombinant viral vector comprises (i) an adeno-associated virus (AAV) backbone of serotype AAV8 and (ii) the telomerase reverse transcriptase (hTERT) gene,
- wherein the second recombinant viral vector comprises (i) an AAV backbone of serotype AAV9 and (ii) the hTERT gene,
- wherein the third recombinant viral vector comprises an AAV backbone of serotype AAV9 and the human klotho (KL) gene, and
- wherein administering the therapeutically effective amount of the first, second, and third recombinant viral vectors increases cognitive function during the first 3.5 months following administration, prevents decline in cognitive function during the first 5 months following administration, or both, as measured by standardized cognitive test scores.
A method for treating age-related cognitive decline in a human, the method comprising:
- intranasally administering a therapeutically effective amount of a first recombinant viral vector, a second recombinant viral vector, and a third recombinant viral vector, each at a dose of at least 2×1013 GC, to a human subject in need thereof,
- wherein the first recombinant viral vector comprises (i) an adeno-associated virus (AAV) backbone of serotype AAV8 and (ii) the telomerase reverse transcriptase (hTERT) gene,
- wherein the second recombinant viral vector comprises (i) an AAV backbone of serotype AAV9 and (ii) the hTERT gene,
- wherein the third recombinant viral vector comprises an AAV backbone of serotype AAV9 and the human klotho (KL) gene,
- wherein the method omits administering any human genes other than hTERT and KL, and
- wherein administering the therapeutically effective amount of the first, second, and third recombinant viral vectors increases cognitive function during the first 3.5 months following administration, prevents decline in cognitive function during the first 5 months following administration, or both, as measured by standardized cognitive test scores.
Dependencies are inferred from the claim text.